Shares of Natera Inc (NASDAQ:NTRA) have been given an average rating of “Buy” by the eleven research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $29.00.
A number of research analysts have recently issued reports on NTRA shares. Morgan Stanley lifted their price objective on shares of Natera from $21.00 to $41.00 and gave the stock an “overweight” rating in a research report on Friday, September 28th. JPMorgan Chase & Co. started coverage on shares of Natera in a research report on Friday, October 5th. They issued a “neutral” rating and a $26.00 price objective on the stock. Canaccord Genuity lifted their price objective on shares of Natera from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday, August 16th. TheStreet raised shares of Natera from a “d” rating to a “c-” rating in a research report on Thursday, August 9th. Finally, Cowen reissued a “buy” rating and set a $30.00 target price on shares of Natera in a research report on Friday, November 9th.
Shares of Natera stock traded up $1.16 on Monday, reaching $18.48. The stock had a trading volume of 706,189 shares, compared to its average volume of 449,167. The company has a quick ratio of 2.32, a current ratio of 2.44 and a debt-to-equity ratio of 1.30. Natera has a 1 year low of $8.60 and a 1 year high of $29.62. The company has a market cap of $1.07 billion, a P/E ratio of -7.70 and a beta of 2.05.
In other Natera news, insider Jonathan Sheena sold 166,667 shares of the business’s stock in a transaction that occurred on Tuesday, October 16th. The shares were sold at an average price of $20.66, for a total transaction of $3,443,340.22. Following the sale, the insider now owns 372,583 shares of the company’s stock, valued at approximately $7,697,564.78. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Matthew Rabinowitz sold 403,462 shares of the business’s stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $24.90, for a total transaction of $10,046,203.80. Following the sale, the chief executive officer now directly owns 1,701,686 shares in the company, valued at approximately $42,371,981.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,014,988 shares of company stock worth $48,674,710. 13.18% of the stock is owned by insiders.
Large investors have recently added to or reduced their stakes in the business. Pacer Advisors Inc. purchased a new stake in Natera during the 3rd quarter worth approximately $106,000. Point72 Hong Kong Ltd purchased a new stake in shares of Natera in the 3rd quarter valued at $119,000. Quantbot Technologies LP purchased a new stake in shares of Natera in the 3rd quarter valued at $135,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Natera in the 2nd quarter valued at $200,000. Finally, Meeder Asset Management Inc. boosted its holdings in shares of Natera by 920.5% in the 3rd quarter. Meeder Asset Management Inc. now owns 8,399 shares of the medical research company’s stock valued at $200,000 after acquiring an additional 7,576 shares during the last quarter. 87.90% of the stock is currently owned by institutional investors.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Article: What is Considered a Good Return on Equity (ROE)?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.